...
首页> 外文期刊>AIDS >Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: Reduced replicating and latent SIV in the brain
【24h】

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: Reduced replicating and latent SIV in the brain

机译:猿猴免疫缺陷病毒感染的猕猴的神经保护性马拉维罗单药治疗:大脑中复制和潜伏SIV减少

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: HIV-associated neurocognitive deficits remain a challenge despite suppressive combined antiretroviral therapy. Given the association between HIV-induced central nervous system (CNS) disease and replication of HIV in immune-activated macrophages, CCR5 antagonists may attenuate CNS disease by modulating inflammatory signaling and by limiting viral replication. Design: To establish whether initiating CCR5 inhibition during early infection altered CNS disease progression, outcomes were compared between simian immunodeficiency virus (SIV)-infected macaques treated with maraviroc (MVC) versus untreated SIV-infected macaques. Methods: Six SIV-infected rhesus macaques were treated with MVC monotherapy for 5 months beginning 24 days postinoculation; 22 SIV-infected animals served as untreated controls. SIV RNA levels in plasma, cerobrospinal fluid, and brain, and CNS expression of TNFa and CCL2 were measured by qRT-PCR. Immunostaining for CD68 and amyloid precursor protein in the brain was measured by image analysis. Plasma sCD163 was measured by ELISA. Results: SIV RNA and proviral DNA levels in brain were markedly lower with MVC treatment, demonstrating CCR5 inhibition reduces CNS replication of SIV and may reduce the CNS latent viral reservoir. MVC treatment also lowered monocyte and macrophage activation, represented by CNS CD68 immunostaining and plasma sCD163 levels, and reduced both TNFa and CCL2 RNA expression in brain. Treatment also reduced axonal amyloid precursor protein immunostaining to levels present in uninfected animals, consistent with neuroprotection. Conclusion: CCR5 inhibitors may prevent neurologic disorders in HIV-infected individuals by reducing inflammation and by limiting viral replication in the brain. Furthermore, CCR5 inhibitors may reduce the latent viral reservoir in the CNS. Adding CCR5 inhibitors to combined antiretroviral regimens may offer multiple neuroprotective benefits.
机译:目的:尽管抑制性联合抗逆转录病毒疗法,与艾滋病毒相关的神经认知功能障碍仍然是一个挑战。考虑到HIV诱导的中枢神经系统(CNS)疾病与免疫激活巨噬细胞中HIV复制之间的关联,CCR5拮抗剂可通过调节炎症信号传导和限制病毒复制来减轻CNS疾病。设计:为了确定在早期感染期间启动CCR5抑制作用是否会改变CNS疾病进展,比较了用maraviroc(MVC)处理的猿猴免疫缺陷病毒(SIV)感染的猕猴与未经处理的SIV感染的猕猴的结果。方法:从接种后24天开始,用MVC单一疗法治疗6只感染SIV的恒河猴,持续5个月。将22只SIV感染的动物用作未治疗的对照。通过qRT-PCR测量血浆,脑脊液和脑中SIV RNA的水平,以及TNFa和CCL2的CNS表达。通过图像分析测量脑中CD68和淀粉样前体蛋白的免疫染色。通过ELISA测量血浆sCD163。结果:MVC治疗可显着降低大脑中SIV RNA和前病毒DNA的水平,这表明CCR5抑制作用会降低SIV的CNS复制,并可能减少CNS潜在病毒库。 MVC治疗还降低了以CNS CD68免疫染色和血浆sCD163水平为代表的单核细胞和巨噬细胞活化,并降低了脑中TNFa和CCL2 RNA的表达。治疗还可以将轴突淀粉样前体蛋白免疫染色降低到未感染动物体内的水平,这与神经保护作用一致。结论:CCR5抑制剂可通过减少炎症和限制脑内病毒复制来预防HIV感染者的神经系统疾病。此外,CCR5抑制剂可能会减少CNS中潜在的病毒库。将CCR5抑制剂加入抗逆转录病毒联合治疗方案可能会提供多种神经保护作用。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号